̽»¨ÊÓƵ

In August 2017, ̽»¨ÊÓƵ TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome."

Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology. RVU120 is a highly selective first-in-class CDK8/CDK19 inhibitor that was discovered with the Ryvu Therapeutics discovery engine platform. CDK8 plays a unique and critical role in gene regulation and is implicated in the development of numerous hematological malignancies and solid tumors.

Ryvu is currently enrolling several Phase 2 clinical trials:

• RVU120 as monotherapy in genetically defined cohorts of patients with relapsed/refractory AML and high-risk myelodysplastic syndromes (RIVER-52, )
• RVU120 in combination with venetoclax for patients with relapsed/ refractory AML (RIVER-81, )
• RVU120 as monotherapy for patients with low-risk myelodysplastic syndromes (REMARK, )
• RVU120 as monotherapy and in combination with ruxolitinib for patients with myelofibrosis (POTAMI-61, )

For more information about Ryvu, visit .

Recent News

• - announced that the first patient has been dosed in the REMARK study, a Phase II clinical trial investigating RVU120 as a monotherapy for the treatment of patients with LR-MDS. 

• - announced that the first patient has been dosed with the study drugs in a Phase 2 clinical trial investigating RVU120 in combination with venetoclax for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) – the RIVER-81 study.

• - named the Warsaw Stock Exchange Company of the Year in a competition organized by the largest business daily in Poland - Puls Biznesu.

• – announced the completion of its public offering of Series J common shares. As a result, Ryvu has obtained gross proceeds of PLN 250.3 million ($57M USD) from institutional and individual investors as well as BioNTech and The Leukemia & Lymphoma Society (̽»¨ÊÓƵ).

•  â€“ announced new data demonstrating clinical and preclinical activity of its selective CDK8/19 inhibitor RVU120 at the 64^th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held on December 10 –13, 2022, in New Orleans, Louisiana.

•  - announced that the data from the Phase 1b dose-escalation study of RVU120 (SEL120) in patients with AML or high-risk myelodysplastic syndromes (HR-MDS) will be presented at the Annual EHA 2022 Hybrid Congress, June 9-17 in Vienna, Austria.